Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | AGER | Q15109 | 4/20 | 0.52 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846881 | 0.91 | DRD2 (0.64) | DRD2DRD3DRD4KMT2AMAPT | |
| SCHEMBL6843585 | 0.90 | DRD2 (0.54) | DRD2DRD3DRD4MAPTAGER | |
| SCHEMBL6846647 | 0.89 | DRD2 (0.53) | DRD2DRD3DRD4KMT2AMAPT | |
| SCHEMBL6839336 | 0.89 | MAPT (0.54) | DRD2DRD3DRD4KMT2AMAPT | |
| SCHEMBL6839537 | 0.88 | RECQL (0.56) | DRD2DRD3DRD4KMT2AMAPT | |
| SCHEMBL6846653 | 0.86 | MEN1 (0.58) | KMT2AMAPTAGERMAPK1SMN1; SMN2 | |
| SCHEMBL6844248 | 0.85 | AGER (0.53) | DRD2DRD3MAPTAGERHTR7 | |
| SCHEMBL6844266 | 0.85 | HTR7 (0.57) | DRD2DRD3DRD4KMT2AMAPT | |
| SCHEMBL6839145 | 0.84 | TDP1 (0.60) | DRD2DRD3DRD4MAPTAGER | |
| SCHEMBL6846830 | 0.84 | AGER (0.49) | DRD2DRD3DRD4KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| EP-0775118-B1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | claimed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | claimed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-5889010-A | PSYCHOLOGICAL DISORDERS; UROGENITAL DISORDERS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; VISION DEFECTS; CONGESTIVE HEART FAILURE; DRUG ABRUSE; PARKINSON'S DISEASE;ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | PFIZER INC. (US) | 1999-03-30 | — | — | US | claimed |
| EP-0775118-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004250-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1996-02-15 | — | — | WO | claimed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| EP-0775118-B1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6548502-B2 | Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5889010-A | PSYCHOLOGICAL DISORDERS; UROGENITAL DISORDERS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; VISION DEFECTS; CONGESTIVE HEART FAILURE; DRUG ABRUSE; PARKINSON'S DISEASE;ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | PFIZER INC. (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0775118-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004250-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD2 3/4885DRD3 6/4885DRD4 2/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD2 3/4885DRD3 6/4885DRD4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.